If you are demanding any product or service please register as Farmavita.Net network member and publish your offer or demad.
In-Licensing and oursoucing of products is usual a way for development of winning portfolio of products. License-in is also very cost effective way of product/technology development.
Opportunities are listed according chronological order, the most recent first.
Member of Farmavita:net offer Dossier and license for Epoprostenol
CTD with supply agreement and marketing authorization
Epoprostenol 0.5 mg and 1.5 mg (Powder and Solvent for Solution for Infusion)
Epoprostenol is indicated for:
Pulmonary Arterial Hypertension Epoprostenol is indicated for the treatment of pulmonary arterial hypertension (PAH) (idiopathic or heritable PAH and PAH ociated with connective tissue diseases) in patients with WHO Functional Cl III-IV symptoms to improve exercise capacity.
Renal Dialysis Epoprostenol is indicated for the use in haemodialysis in emergency situations when use of heparin carries a high risk of causing or exacerbating bleeding or when heparin is otherwise contraindicated.